CRISPR Therapeutics’s Competitors, Revenue, Number of Employees, Funding, Acquisitions & News

CRISPR Therapeutics develops and commercializes gene-based medicines for the treatment of serious diseases. Read more

CRISPR Therapeutics develops and commercializes gene-based medicines for the treatment of serious diseases. Read more

Samarth Kulkarni's photo - CEO of CRISPR Therapeutics

CEO

Samarth Kulkarni

CEO Approval Rating

96/100

Founded:

2013

Status:

PublicNASDAQCRSP

Annual Revenue
Employees
Headquarters
,
Zug

TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

Editas Medicine is CRISPR Therapeutics's #1 competitor. Editas Medicine was founded in Cambridge, Massachusetts} in 2013. Editas Medicine operates in the Pharmaceuticals industry. Compared to CRISPR Therapeutics, Editas Medicine generates $266.5M less revenue.

eGenesis is one of CRISPR Therapeutics's top competitors. eGenesis was founded in 2015 in Cambridge, Massachusetts. eGenesis operates in the Biotechnology industry. eGenesis generates $269.1M less revenue than CRISPR Therapeutics.

Intellia Therapeutics is a top competitor of CRISPR Therapeutics. Intellia Therapeutics was founded in 2014, and is headquartered in Cambridge, Massachusetts. Like CRISPR Therapeutics, Intellia Therapeutics also competes in the Life Sciences industry. Intellia Therapeutics generates $238.2M less revenue vs. CRISPR Therapeutics.

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is Haplomics a competitor of CRISPR Therapeutics?

Quarterly and Annual Revenue

Trailing 12-Months Trend (TTM)

Annual Revenue

$289.1M

CRISPR Therapeutics's revenue is the ranked 1st among it's top 10 competitors. The top 10 competitors average 47.4M. Over the last four quarters, CRISPR Therapeutics's revenue has decreased by 100%. Specifically, in Q2 2020's revenue was $ < 1M; in Q1 2020, it was $ < 1M; in Q4 2019, it was $77M; in Q3 2019, CRISPR Therapeutics's revenue was $211.9M.

Acquisitions

No recent acquisitions found related to CRISPR Therapeutics

CRISPR Therapeutics Funding History

$25M$89M$218M

Since CRISPR Therapeutics was founded in 2013, it has participated in 6 rounds of funding. In total CRISPR Therapeutics has raised $218.0M. CRISPR Therapeutics' last funding round was on Oct 2016 for a total of $35.0M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Equity
Oct 2016
$35M
-
IPO
Oct 2016
$56M
-
Series B
Jun 2016
$38M
Series B
Apr 2015
$29M
Series A
Apr 2015
$35M

Total Funding: $218M

Since CRISPR Therapeutics was founded in 2013, it has participated in 6 rounds of funding. In total CRISPR Therapeutics has raised $218.0M. CRISPR Therapeutics' last funding round was on Oct 2016 for a total of $35.0M

Investments

No recent investments found related to CRISPR Therapeutics

CRISPR Therapeutics News

October 21, 2020BioPharma Dive

CRISPR Therapeutics reports remissions, one death in cancer cell therapy study

The biotech is one of several attempting to develop so-called "off-the-shelf" CAR-T therapies. While ... See more »
October 1, 2020MarketScreener

Corporate Presentation

(marketscreener.com) ® Creating transformative gene-based medicines for serious diseases Corporate Ov... See more »
September 23, 2020PharmaTimes

Vertex, CRISPR Therapeutics' sickle cell gene therapy wins PRIME designation

European Medicines Agency grants designation based on phase I/II data... See more »
September 9, 2020Zolmax News

Advisors Asset Management Inc. Purchases New Position in Crispr Therapeutics AG (NASDAQ:CRSP)

Advisors Asset Management Inc. purchased a new stake in shares of Crispr Therapeutics AG (NASDAQ:CRSP... See more »

CRISPR Therapeutics Press Releases

February 26, 2020GlobeNewswire

CRISPR Therapeutics Proposes Changes to the Board of Directors

ZUG, Switzerland and CAMBRIDGE, Mass., Feb. 26, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq:... See more »
July 29, 2019GlobeNewswire

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2019 Financial Results

-Provides update in ongoing Phase 1/2 clinical trials of CTX001® for patients with severe hemoglobino... See more »
April 29, 2019GlobeNewswire

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2019 Financial Results

-Enrollment ongoing in Phase 1/2 clinical trials of CTX001 for patients with severe hemoglobinopathie... See more »
March 6, 2019CentralCharts

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

ZUG, Switzerland and CAMBRIDGE, Mass., March 06, 2019 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq... See more »
February 19, 2019GlobeNewswire

CRISPR Therapeutics and StrideBio Expand Exclusive Development and Option Agreement

--Expansion of Collaboration to Focus on the Development of Novel Capsids for Additional Applications... See more »
November 7, 2018GlobeNewswire

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2018 Financial Results

-Initiated Phase 1/2 Clinical Trial of CTX001 in β-thalassemia- -Targeting Initiation of Clinical Tri... See more »
August 30, 2018GlobeNewswire

CRISPR Therapeutics to Present at Upcoming Investor Conferences

ZUG, Switzerland and CAMBRIDGE, Mass., Aug. 30, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:... See more »

Headquarters

Baarerstrasse 14

ZUG, ZugV8 CH-6300

617-315-4600

Driving Directions »

Trending Companies

Summary

ABOUT

Overview

CRISPR Therapeutics develops and commercializes gene-based medicines for the treatment of serious diseases. CRISPR Therapeutics was founded in 2013. CRISPR Therapeutics' headquarters is located in ZUG, Zug, CH V8 CH-6300. It has raised 218.0M in 6 rou...

CEO

CRISPR Therapeutics's CEO, Samarth Kulkarni, currently has an approval rating of 96%. CRISPR Therapeutics's primary competitors are Editas Medicine, eGenesis & Intellia Therapeutics.

Website

crisprtx.com

Frequently Asked Questions about CRISPR Therapeutics

  1. When was CRISPR Therapeutics founded?

    CRISPR Therapeutics was founded in 2013
  2. Who is CRISPR Therapeutics's CEO?

    CRISPR Therapeutics's CEO is Samarth Kulkarni
  3. How much revenue does CRISPR Therapeutics generate?

    CRISPR Therapeutics generates $289.1M in revenue
  4. How much funding does CRISPR Therapeutics have?

    CRISPR Therapeutics has historically raised $218M in funding
  1. Where is CRISPR Therapeutics's headquarters?

    CRISPR Therapeutics's headquarters is in ZUG Zug, CH
  2. How many employees does CRISPR Therapeutics have?

    CRISPR Therapeutics has 188 employees
  3. What sector does CRISPR Therapeutics operate in?

    CRISPR Therapeutics is in Life Sciences
  4. Who are CRISPR Therapeutics's competitors?

    CRISPR Therapeutics's top competitors are Editas Medicine, eGenesis, Intellia Therapeutics